5 Stocks Pushing The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.5%) at 15,564 as of Friday, Sept. 20, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 854 issues advancing vs. 2,087 declining with 92 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. Top gainers within the industry include Allergan ( AGN), up 1.7%, Shire ( SHPG), up 1.1%, Alexion Pharmaceuticals ( ALXN), up 1.1%, GlaxoSmithKline ( GSK), up 0.7% and Sanofi ( SNY), up 0.7%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 0.9%, and Valeant Pharmaceuticals International ( VRX), down 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Sarepta Therapeutics ( SRPT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sarepta Therapeutics is up $5.70 (15.5%) to $42.39 on heavy volume. Thus far, 8.9 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $36.07-$43.60 after having opened the day at $37.79 as compared to the previous trading day's close of $36.69.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.2 billion and is part of the health care sector. Shares are up 43.5% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Sarepta Therapeutics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, AstraZeneca ( AZN) is up $0.31 (0.6%) to $52.13 on average volume. Thus far, 678,305 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $52.08-$52.33 after having opened the day at $52.23 as compared to the previous trading day's close of $51.82.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $64.2 billion and is part of the health care sector. Shares are up 8.5% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates AstraZeneca a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Novartis ( NVS) is up $0.59 (0.8%) to $76.70 on average volume. Thus far, 724,418 shares of Novartis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $76.55-$76.93 after having opened the day at $76.85 as compared to the previous trading day's close of $76.11.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $184.0 billion and is part of the health care sector. Shares are up 18.8% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.29 (0.8%) to $37.72 on light volume. Thus far, 1.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $37.41-$37.81 after having opened the day at $37.45 as compared to the previous trading day's close of $37.43.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $31.8 billion and is part of the health care sector. Shares are up 0.7% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is up $1.40 (0.9%) to $149.92 on heavy volume. Thus far, 3.0 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $148.11-$151.95 after having opened the day at $149.00 as compared to the previous trading day's close of $148.52.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $60.5 billion and is part of the health care sector. Shares are up 89.5% year to date as of the close of trading on Thursday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower